Premium
Exacerbation of symptoms of autoimmune disease in patients receiving alpha‐interferon therapy
Author(s) -
Conlon Kevin C.,
Urba Walter J.,
Smithii John W.,
Steis Ronald G.,
Longo Dan L.,
Clark Jeffrey W.
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900515)65:10<2237::aid-cncr2820651013>3.0.co;2-5
Subject(s) - medicine , exacerbation , autoantibody , subclinical infection , immunology , autoimmune thyroiditis , thyroiditis , alpha interferon , autoimmune disease , disease , interferon , antibody
The occurrence of autoimmune disease in patients receiving alpha‐interferon (α:‐IFN) therapy has been reported in several studies; these include autoimmune thyroiditis, thrombocytopenia, anemia, exacerbation of psoriasis, and the occurrence of sarcoidosis. The primary mechanism presumably is the emergence of autoantibodies to various structural proteins or receptors. Two studies have recently shown that a significant percentage of patients treated with recombinant alpha‐interferon (r α‐IFN) do form autoantibodies. The authors report six additional cases of development or exacerbation of autoimmune phenomena in patients receiving α‐IFN therapy. Five of these patients developed symmetric polyarthropathies and the sixth had thyroiditis. The presence of a history of underlying autoimmune disease or baseline serologic abnormalities in five of these patients, including the patient who developed thyroiditis, suggests that α‐IFN treatment can lead to the exacerbation of an underlying subclinical autoimmune process.